OXiGENE Data Shows Median Survival, One-Year Survival Improvement in Anaplastic Thyroid Cancer Patients Treated With Zybrestat, Chemotherapy

OXiGENE announced that data were presented from a pre-specified subgroup analysis of the FACT trial, a randomized, controlled Phase II/III study of Zybrestat (fosbretabulin tromethamine) in patients with anaplastic thyroid cancer (ATC).
MarketWatch